ADHD. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: Duloxetine, 30-60 mg/day, starting dose 30 mg/day for 1 week and 60 mg/day for the following 5 weeks. Intervention 2: Methylphenidate, starting dose: 10 mg/ day divided in two doses fo
Treatment - Drugs
Duloxetine, 30-60 mg/day, starting dose 30 mg/day for 1 week and 60 mg/day for the following 5 weeks
Methylphenidate, starting dose: 10 mg/ day divided in two doses for 1 week and 20, 30 and 40 mg/day divided in 3 doses in weeks 2, 3 and 4 respectively according to the patient tolerance and continue
Sponsors
Tehran University of Medical Sciences and Health services
Eligibility
Sex/Gender
All
Age
11 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diagnosis of ADHD according to DSM-IV-TR Criteria, age range of 11 to 18 years Exclusion criteria: Presence of mental retardation, cardiac problems, known contraindications to study drugs, Comorbidity of severe major depression, conduct disorder, bipolar or psychotic disorders, epilepsy taking anticonvulsants at the time of enrollment and during the trial, pregnancy or lactation, refusal to participate
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADHD severity of symptoms. Timepoint: Baseline, Every 2 weeks, End point. Method of measurement: Conner's and ADHD rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects. Timepoint: every 2 weeks and end point. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Javad Mahmoudi-Gharaei
Tehran University of Medical Sciences
Outcome results
None listed